Showing 7731-7740 of 9133 results for "".
- Prolactin Receptor Blockade May Promote Hair Growth via Follicular Stem Cell Activationhttps://practicaldermatology.com/news/prolactin-receptor-blockade-may-promote-hair-growth-via-follicular-stem-cell-activation/2485612/Blocking prolactin receptor (PRLR) signaling with the investigational antibody ABS-201 promoted hair follicle growth and stem cell activation in human male scalp skin models, according to preclinical data from Jérémy Chéret, PhD, MSc, at the South Beach Symposium
- Delgocitinib Improves Patient-Reported Outcomes Across Chronic Hand Eczema Subtypeshttps://practicaldermatology.com/news/delgocitinib-improves-patient-reported-outcomes-across-chronic-hand-eczema-subtypes/2485611/Patient-reported outcome (PRO) data from the phase 3 DELTA 1 and DELTA 2 trials suggest that topical delgocitinib cream provides clinically meaningful symptom relief across major subtypes of chronic hand eczema (CHE), according to a poster from Robert Bissonnette,
- FDA Accepts Galderma’s RelabotulinumtoxinA BLA Resubmissionhttps://practicaldermatology.com/news/fda-accepts-galdermas-relabotulinumtoxina-bla-resubmission/2485601/Galderma announced that the US Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for relabotulinumtoxinA (Relfydess™) for the temporary improvement of moderate-to-severe glabellar lines and lateral canthal lines in a
- Analysis: ChatGPT and DeepSeek Largely Align With Psoriasis Treatment Guidelineshttps://practicaldermatology.com/news/analysis-chatgpt-and-deepseek-largely-align-with-psoriasis-treatment-guidelines/2485578/Large language models (LLMs) ChatGPT and DeepSeek generally adhere to established psoriasis treatment guidelines, but some performance gaps remain. Investigators publishing in the Journal of Drugs in Dermatology exp
- Imagining a Better Future for Hidradenitis Suppurativahttps://practicaldermatology.com/news/imagining-a-better-future-for-hidradenitis-suppurativa/2485556/Hidradenitis suppurativa (HS) has long been misunderstood, underdiagnosed, and undertreated. However, at a recent panel discussion led by Vivian Shi, MD, at
- Icotrokinra Maintains Psoriasis Responses With Continuous Treatmenthttps://practicaldermatology.com/news/icotrokinra-maintains-psoriasis-responses-with-continuous-treatment/2485554/Continuous treatment with icotrokinra resulted in durable psoriasis control through one year, while treatment withdrawal was associated with rapid loss of response, according to “Maintenance of Response With Icotrokinra for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results From the Ph
- Povorcitinib Improves Lesion Burden and Pain in Hidradenitis Suppurativahttps://practicaldermatology.com/news/povorcitinib-improves-lesion-burden-and-pain-in-hidradenitis-suppurativa/2485551/Oral povorcitinib produced early and sustained improvements in lesion burden and pain in patients with moderate-to-severe hidradenitis suppurativa (HS), according to “Effect of Povorcitinib on Hidradenitis Suppurativa Lesions Through 24 Weeks in STOP-HS Trials,” a poster by Jennifer L. Hsiao, MD,
- Dupilumab Produces Early and Sustained Improvements in CSU Activityhttps://practicaldermatology.com/news/dupilumab-produces-early-and-sustained-improvements-in-csu-activity/2485548/Dupilumab produced early and sustained reductions in urticaria activity in patients with chronic spontaneous urticaria (CSU), according to “Dupilumab Provides Early and Sustained Improvement in Urticaria Activity in Patients With Chronic Spontaneous Urticaria,” a poster by Jonathan A. Bernstein,
- Arcutis Reports Positive Phase 2 Data for Infant Atopic Dermatitis Programhttps://practicaldermatology.com/news/arcutis-reports-positive-phase-2-data-for-infant-atopic-dermatitis-program/2485557/Arcutis Biotherapeutics reported positive topline results from the phase 2 INTEGUMENT-INFANT trial evaluating investigational ZORYVE® (roflumilast) cream 0.05% in infants aged 3 months to younger than 24 months with mild to moderate atopic dermatitis (AD).
- Envudeucitinib Enables Durable Treat-to-Target Control in Plaque Psoriasishttps://practicaldermatology.com/news/envudeucitinib-enables-durable-treat-to-target-control-in-plaque-psoriasis/2485542/Envudeucitinib enabled a high proportion of patients with moderate-to-severe plaque psoriasis to achieve and maintain stringent treat-to-target thresholds through one year of therapy, according to “Achievement of Treat-to-Target Thresholds With Envudeucitinib in Moderate-to-Severe Plaque Psoriasi